{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:03:55Z","timestamp":1792047835914,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Australian and New Zealand Journal of Public Health"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.anzjph.2026.100596","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:28:19Z","timestamp":1791941299000},"page":"100596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Paying for access? The Australian research-based pharmaceutical industry\u2019s federal political financial contributions 2015\u20132024"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3953-5518","authenticated-orcid":false,"given":"Daniel","family":"Moses","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5295-0751","authenticated-orcid":false,"given":"Cassandra","family":"de Lacy-Vawdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8671-915X","authenticated-orcid":false,"given":"Barbara","family":"Mintzes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1330-863X","authenticated-orcid":false,"given":"M Mofizul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8021-9130","authenticated-orcid":false,"given":"Deborah","family":"Gleeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.anzjph.2026.100596_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.anzjph.2023.100073","article-title":"Commercial lobbying and political contributions: an Australian scoping review","volume":"47","author":"Lacy-Nichols","year":"2023","journal-title":"Aust N Z J Publ Health"},{"key":"10.1016\/j.anzjph.2026.100596_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.najef.2018.10.006","article-title":"Two faces of corporate lobbying: evidence from the pharmaceutical industry","volume":"51","author":"Unsal","year":"2020","journal-title":"N Am J Econ Finance"},{"key":"10.1016\/j.anzjph.2026.100596_bib3","first-page":"196","volume":"vol. 29","author":"Johnson","year":"2021"},{"issue":"5","key":"10.1016\/j.anzjph.2026.100596_bib4","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jamainternmed.2020.0146","article-title":"Lobbying expenditures and campaign contributions by the pharmaceutical and health product industry in the United States, 1999-2018","volume":"180","author":"Wouters","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.anzjph.2026.100596_bib5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/eurpub\/ckz197","article-title":"Bringing the commercial determinants of health out of the shadows: a review of how the commercial determinants are represented in conceptual frameworks","volume":"30","author":"Maani","year":"2020","journal-title":"Eur J Publ Health"},{"issue":"10383","key":"10.1016\/j.anzjph.2026.100596_bib6","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0140-6736(23)00013-2","article-title":"Defining and conceptualising the commercial determinants of health","volume":"401","author":"Gilmore","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.anzjph.2026.100596_bib7","first-page":"7723","article-title":"Power and other commercial determinants of health: an empirical study of the Australian food, alcohol, and gambling industries","volume":"12","author":"De Lacy-Vawdon","year":"2023","journal-title":"Int J Health Pol Manag"},{"key":"10.1016\/j.anzjph.2026.100596_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthpol.2023.104860","article-title":"Illustrating the impact of commercial determinants of health on the global COVID-19 pandemic: thematic analysis of 16 country case studies","volume":"134","author":"Freeman","year":"2023","journal-title":"Health Policy"},{"issue":"1","key":"10.1016\/j.anzjph.2026.100596_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12992-022-00900-x","article-title":"A proposal for systematic monitoring of the commercial determinants of health: a pilot study assessing the feasibility of monitoring lobbying and political donations in Australia","volume":"19","author":"Lacy-Nichols","year":"2023","journal-title":"Glob Health"},{"issue":"6","key":"10.1016\/j.anzjph.2026.100596_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/heapro\/daaf193","article-title":"Adverse commercial determinants of health in low- and middle-income countries: a public health challenge","volume":"40","author":"Islam","year":"2025","journal-title":"Health Promot Int"},{"issue":"7","key":"10.1016\/j.anzjph.2026.100596_bib11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.healthpol.2021.04.015","article-title":"Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries","volume":"125","author":"Mulinari","year":"2021","journal-title":"Health Policy"},{"key":"10.1016\/j.anzjph.2026.100596_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev-publhealth-090419-102616","article-title":"More than a nuisance: implications of food marketing for public health efforts to curb childhood obesity","volume":"45","author":"Harris","year":"2024","journal-title":"Annu Rev Publ Health"},{"issue":"8","key":"10.1016\/j.anzjph.2026.100596_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.5694\/mja2.52284","article-title":"Pharmaceutical company payments to Australian doctors reported to medicines Australia, 2019\u201322: a cross-sectional analysis","volume":"220","author":"Forbes","year":"2024","journal-title":"Med J Aust"},{"key":"10.1016\/j.anzjph.2026.100596_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078133","article-title":"Raising the bar for disclosure of industry payments to doctors","volume":"384","author":"Menkes","year":"2024","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.anzjph.2026.100596_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/0020731418823376","article-title":"Pharmaceutical industry funding of health consumer groups in Australia: a cross-sectional analysis","volume":"49","author":"Fabbri","year":"2019","journal-title":"Int J Health Serv"},{"key":"10.1016\/j.anzjph.2026.100596_bib16","article-title":"Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study","volume":"383","author":"Mitchell","year":"2023","journal-title":"Bmj"},{"key":"10.1016\/j.anzjph.2026.100596_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.25259\/SNI_377_2022","article-title":"The pharmaceutical industry is dangerous to health. Further proof with COVID-19","volume":"13","author":"Deruelle","year":"2022","journal-title":"Surg Neurol Int"},{"issue":"4","key":"10.1016\/j.anzjph.2026.100596_bib18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s11948-018-0041-5","article-title":"Medicines information and the regulation of the promotion of pharmaceuticals","volume":"25","author":"Leonardo","year":"2019","journal-title":"Sci Eng Ethics"},{"key":"10.1016\/j.anzjph.2026.100596_bib19","series-title":"Review of pharmaceutical companies","year":"2019"},{"issue":"3","key":"10.1016\/j.anzjph.2026.100596_bib20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/16066359.2020.1766449","article-title":"Measuring influence: an analysis of Australian gambling industry political donations and policy decisions","volume":"29","author":"Johnson","year":"2021","journal-title":"Addiction Res Theor"},{"issue":"3","key":"10.1016\/j.anzjph.2026.100596_bib21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/dar.12878","article-title":"\u2018If someone donates $1000, they support you. If they donate $100 000, they have bought you\u2019. Mixed methods study of tobacco, alcohol and gambling industry donations to Australian political parties","volume":"38","author":"Kypri","year":"2019","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.anzjph.2026.100596_bib22","series-title":"Transparency register","year":"2024"},{"key":"10.1016\/j.anzjph.2026.100596_bib23","series-title":"Annual reports","year":"2024"},{"key":"10.1016\/j.anzjph.2026.100596_bib24","series-title":"Membership information","year":"2024"},{"key":"10.1016\/j.anzjph.2026.100596_bib25","series-title":"Political donations","year":"2024"},{"key":"10.1016\/j.anzjph.2026.100596_bib26","series-title":"Inflation calculator","year":"2024"},{"key":"10.1016\/j.anzjph.2026.100596_bib27","series-title":"Facts book 2021","year":"2021"},{"key":"10.1016\/j.anzjph.2026.100596_bib28","series-title":"PBS expenditure and prescriptions report 1 July 2023 to 30 June 2024","year":"2024"},{"issue":"8","key":"10.1016\/j.anzjph.2026.100596_bib29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.5694\/mja2.52284","article-title":"Pharmaceutical company payments to Australian doctors reported to medicines Australia, 2019-22: a cross-sectional analysis","volume":"220","author":"Forbes","year":"2024","journal-title":"Med J Aust"},{"key":"10.1016\/j.anzjph.2026.100596_bib30","first-page":"7292","article-title":"Corporate political activity: taxonomies and model of corporate influence on public policy","volume":"12","author":"Ulucanlar","year":"2023","journal-title":"Int J Health Pol Manag"},{"issue":"3","key":"10.1016\/j.anzjph.2026.100596_bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/M20-5665","article-title":"Are financial payments from the pharmaceutical industry associated with physician prescribing? : a systematic review","volume":"174","author":"Mitchell","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.anzjph.2026.100596_bib32","article-title":"Industry funding of patient and health consumer organisations: systematic review with meta-analysis","volume":"368","author":"Fabbri","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.anzjph.2026.100596_bib33","article-title":"State capture: top corporations identified as members of both liberal and labor parties","author":"Tran","year":"2021","journal-title":"Michael West Media"},{"key":"10.1016\/j.anzjph.2026.100596_bib34","series-title":"Electoral Act (Vic)","year":"2002"},{"key":"10.1016\/j.anzjph.2026.100596_bib35","series-title":"Electoral Funding Act (NSW)","year":"2018"},{"key":"10.1016\/j.anzjph.2026.100596_bib36","series-title":"Electoral Act (Qld)","year":"1992"},{"key":"10.1016\/j.anzjph.2026.100596_bib37","series-title":"Australian associated press","author":"Canales","year":"2024"}],"container-title":["Australian and New Zealand Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1326020026002852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1326020026002852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:28:27Z","timestamp":1791941307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1326020026002852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"alternative-id":["S1326020026002852"],"URL":"https:\/\/doi.org\/10.1016\/j.anzjph.2026.100596","relation":{},"ISSN":["1326-0200"],"issn-type":[{"value":"1326-0200","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paying for access? The Australian research-based pharmaceutical industry\u2019s federal political financial contributions 2015\u20132024","name":"articletitle","label":"Article Title"},{"value":"Australian and New Zealand Journal of Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anzjph.2026.100596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Public Health Association of Australia.","name":"copyright","label":"Copyright"}],"article-number":"100596"}}